ANGLE plc (LON:AGL) had its Corporate rating reiterated by FinnCap

Analyst Ratings For ANGLE plc (LON:AGL)

Story continues below

Today, FinnCap reiterated its Corporate rating on ANGLE plc (LON:AGL).

There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.

The current consensus rating on ANGLE plc (LON:AGL) is N/A with a consensus target price of GBX 110 per share, a potential .

Some recent analyst ratings include

  • 2/25/2019-ANGLE plc (LON:AGL) had its Corporate rating reiterated by FinnCap
  • 7/5/2017-ANGLE plc (LON:AGL) had its Speculative Buy rating reiterated by Beaufort Securities

    About ANGLE plc (LON:AGL)
    ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests rare circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application and others. The company was founded in 2004 and is based in Guildford, the United Kingdom.

    Recent Trading Activity for ANGLE plc (LON:AGL)
    Shares of ANGLE plc closed the previous trading session at 55,50 0,00 0,00 % with shares trading hands.

    An ad to help with our costs